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Abstract
Background: Klebsiella pneumoniae is a family member of Enterobacteriaceae. Isolates of K. pneumoniae produce enzymes that
cause decomposition of third generation cephalosporins. These enzymes are known as extended-spectrum beta-lactamase (ESBL).
Resistance of K. pneumoniae to beta-lactamase antibiotics is commonly mediated by beta-lactamase genes.
Objectives: The aim of this study was to identify the ESBL produced by K. pneumoniae isolates that cause community-acquired and
nosocomial urinary tract infections within a one-year period (2013 to 2014) in Kashani and Hajar university hospitals of Shahrekord,
Iran.
Patients and Methods: From 2013 to 2014, 150 strains of K. pneumoniae isolate from two different populations with nosocomial
and community-acquired infections were collected. The strains were then investigated by double disk synergism and multiplex
polymerase chain reaction (PCR).
Results: The study population of 150 patients with nosocomial and community-acquired infections were divided to two groups
of 75 each. We found that 48 of the K. pneumoniae isolates in the patients with nosocomial infection and 39 isolates in those with
community-acquired infections produced ESBL. The prevalence of TEM1, SHV1 and VEB1 in ESBL-producing isolates in nosocomial
patients was 24%, 29.3% and 10.6%, and in community-acquired patients, 17.3%, 22.7% and 8%, respectively.
Conclusions: The prevalence of ESBL-producing K. pneumoniae isolate is of great concern; therefore, continuous investigation seems
essential to monitor ESBL-producing bacteria in patients with nosocomial and community-acquired infections.
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1. Background
Urinary tract infections (UTIs) are one of the most fre-
quent infections in patients admitted to hospitals (1). Kleb-
siella pneumoniae are opportunistic bacteria responsible
for different infections such as pneumonia, UTIs and sep-
ticemia in nosocomial and community environments (2).
Beta-lactam drugs that have a beta-lactam ring in their
composition are used extensively to save the lives of pa-
tients with bacterial diseases (3).
Since the 1980s, beta-lactam antibiotics such as
oxyimino-cephalosporins have been used for the treat-
ment of Gram-negative bacterial infections (4). Unfor-
tunately, nowadays, beta lactamase resistance has been
growing among members of Enterobacteriaceae, includ-
ing Escherichia coli and K. pneumoniae. Meanwhile, the most
common cause of beta-lactam resistance is beta-lactamase
enzymes, which deactivate beta-lactam drugs by break-
ing down the beta lactam ring (5). Extended-Spectrum
beta-lactamases (ESBLs) are a class of enzymes that are
encoded by the plasmid, which hydrolyze a wide variety of
cephalosporins such as cefotaxime, ceftazidime, ceftriax-
one and drugs that have the beta-lactam ring within their
structure (6). Extended-Spectrum beta-lactamases were
first identified in the early 1980s among Klebsiella species
and subsequently in Escherichia coli, Serratia marcescens,
Pseudomonas aeruginosa and other Gram-negative bacilli
(7, 8).
Infections caused by Gram-negative bacteria produc-
ing ESBLs have become a serious problem for hospitals
worldwide (9). So far, about 400 different types of ES-
BLs have been recognized around the world, among which
TEM and SHV were more prevalent (10). Mutations oc-
curring in the genes encoding TEM and SHV enzymes
lead to the development of ESBLs that have an expanded
substrate profile, which allows for the hydrolysis of all
cephalosporins, penicillins and aztreonam (11). These en-
zymes are most commonly produced by Klebsiella spp.
Other beta lactamase enzymes are less prevalent (12). VEB
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can hydrolyze cefotaxime, ceftazidime and monobactams.
These enzymes cause durability of various bacterial infec-
tions including UTIs in patients (13).
The blaVEB-1-like genes are present as a gene cassette
on class 1 integrons that vary in size and structure. In
most cases, the VEB-1 cassette has been associated with an
arr-2 cassette (rifampin resistance), aminoglycoside resis-
tance gene cassettes, and an OXA-10-like cassette encoding
a narrow-spectrum oxacillinase-type beta-lactamase. The
blaVEB-1 gene has been reported in several enterobacte-
rial isolates from Asia. Furthermore, VEB-1 ESBL was iden-
tified in Vietnam among P. aeruginosa and Enterobacte-
riaceae isolates (14). Therapeutic options for infections
due to ESBL-producing bacteria have also become increas-
ingly limited (8). Phenotypic and molecular detection of
ESBL genes such as SHV and TEM can yield appropriate
data regarding the epidemiology and risk factors of ESBL-
producing bacteria (7, 15).
2. Objectives
Because of the prevalence of beta-lactamase genes
in K. pneumoniae isolate and lack of enough informa-
tion about outbreak of these genes in K. pneumoniae iso-
lates in Shahrekord, this study was conducted to deter-
mine the prevalence of TEM, SHV and VEB genes in ESBL-
positive K. pneumoniae strains isolated from nosocomial
and community-acquired UTIs in Kashani and Hajar uni-
versity hospitals of Shahrekord, Iran.
3. Patients andMethods
3.1. Data Collection
Over 436 urine samples were collected from differ-
ent wards (infant, internal, intensive care unit, surgery,
emergency, etc.). The isolates were collected from July,
2013 to October, 2014 from two educational hospitals
in Shahrekord, Iran. The present study was conducted
by the department of microbiology and immunology of
the faculty of medicine and cellular and molecular re-
search center of Shahrekord University of Medical Sci-
ences, Shahrekord, Iran. One hundred and fifty isolates
of K. pneumoniae bacteria were selected from nosocomial
and community-acquired infections in the hospitals un-
der study. Clinical urine samples of patients with UTI were
used to isolate bacteria for the study.
3.2. Inclusion and Exclusion Criteria
The patients with a positive urine sample for Klebsiella
at admission and history of hospitalization for less than
two weeks were considered as outpatients. These patients
could be symptomatic or asymptomatic for UTI. However,
the patients with primary negative urine culture, who
were hospitalized for several reasons rather than UTI (in-
cluding diabetes, cardiac ischemia, and pregnancy) and
whose urine culture grew positive for Klebsiella after 48 -
72 hours, were considered as inpatients. Nosocomial in-
fections are infections developed after patient’s admission
to the hospital while the patient should not present UTI
symptoms at admission.
3.3. Isolation and Identification of Bacteria
Klebsiella pneumoniae isolates were identified through
culture, Gram stain, and microscopy and biochemical stan-
dard tests. Blood agar, eosin methylene blue media, and
MacConkey agar (Merck Co., Germany) were used for cul-
ture. Uropathogenic microorganisms were identified via
phenotypic tests of specific culture and typical phenotypic
features. Bacterial isolates were then identified by Gram
staining (identifying Gram positive or Gram-negative or-
ganisms) and a series of standard biochemical tests.
3.4. Antimicrobial Drugs Susceptibility Assay
An antibiotic susceptibility assay was performed via
the disk diffusion method (Kirby Bauer), according to
the clinical laboratory standards institute criteria (16) on
Mueller-Hinton agar plates (Merk Co., Germany). The
discs of antibacterial agents used in this study contained
amikacin (30 µg), norfloxacin (10 µg), imipenem (30 µg),
ceftriaxone (30 µg), ceftazidime (30 µg), cefepime (30
µg), nalidixic acid (30 µg), ciprofloxacin (5 µg), gentam-
icin (10 µg), nitrofurantoin (300 µg) and trimethoprim-
sulfamethoxazole (1.25/23.75 µg). All the antibiotics were
obtained from Mast laboratories (MAST, UK). Diameters of
the zones of inhibition for individual antibacterial agents
were translated into susceptible, intermediate, and resis-
tant categories, according to the clinical and laboratory
standards institute (CLSI) criteria (16). Multiple drug resis-
tant microorganisms were identified as resistant to three
or more antibacterial classes. Isolates showing inhibition
zones of ≤ 27 mm for cefotaxime and ≤ 22 mm for cef-
tazidime were screened as potential ESBL producers.
3.5. Detection of Extended-Spectrum Beta-Lactamase-
Producing Microorganisms
In order to ensure the accuracy of ESBL-producing or-
ganisms, K. pneumoniae ATCC 700603 was used as the ESBL-
positive and E. coli ATCC 25922 was used as the negative
control. The ESBL production was determined using the
double disc synergy test. The ESBL-positive strains were
detected with phenotypic confirmatory tests using DDST,
which contained third generation cephalosporins both
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with and without clavulanic acid. The discs used contained
ceftazidime (30 µg) and ceftazidime + clavulanic acid (30
µg + 10 µg) (MAST, UK). The differences in the zone of inhi-
bition caused by the cephalosporins alone and combined
with clavulanic acid were recorded, and if the difference
was 5 mm or greater, the strains were confirmed as ESBL-
producing.
3.6. Minimal Inhibitory Concentration (MIC) Testing
The MIC for cefotaxime, ceftazidime and ceftriaxone
were determined via the E-test (Liofilchem MIC Test Strips,
Italy). The E-test has been reported to be a simple and ac-
curate alternative method for determining the antimicro-
bial susceptibility of various microorganisms. The MIC for
cefotaxime, ceftazidime and ceftriaxone was determined,
according to the national committee for clinical labora-
tory standards criteria (16) for phenotypic ESBL-producing
K. pneumoniae isolates from UTIs using the E-test strip.
3.7. Preparation of DNA Template for Multiplex Polymerase
Chain Reaction
Since most ESBL-producing genes are plasmid-
dependent, we used the GeNet bio plasmid kit (plasmid
DNA isolation kit, Korea) to extract and purify the plasmid
DNA. To extract plasmid DNA, the bacteria were incubated
overnight in 5 mL of lysogeny broth at 37°C. Plasmid
DNA extraction was based on the GeNet bio plasmid kit
protocol. Plasmid DNA concentrations were determined
by BioPhotometer (Eppendorf). The extracted DNA was
stored under sterile conditions at -20°C (Table 1).
3.8. Multiplex Polymerase Chain Reaction for Beta-Lactamase-
Encoding Genes
Multiplex PCR for beta-lactamase genes TEM1, SHV1, and
VEB1 was performed. Sequences of primers used for the
multiplex PCR of the genes are listed in Table 2. The mul-
tiplex PCR was optimized according to the following ex-
perimental conditions: initial denaturation at 95°C for five
minutes, 35 cycles of 94°C for 30 seconds, 56°C for 30 sec-
onds, and 72°C for 40 seconds, followed by a final extension
step at 72°C for five minutes and holding a one-time cycle
at 4°C for five minutes.
4. Results
The study population of 150 patients with nosocomial
and community-acquired infections were divided to two
groups of 75 each. An antibiotic susceptibility assay was
performed using disc antibacterial agents. The results are
shown in Table 3.
Of the 75 nosocomial samples, at least 54 (71.6%) isolates
were resistant to three drug classes. Of these samples, 48
(64%) samples were ESBL-positive. Of the 75 community-
acquired samples, 41 (54.9%) isolates were multiple drug re-
sistant. Of these samples, 36 (48%) were ESBL-positive (Fig-
ure 1).
Figure 1. Frequency of Extended-Spectrum Beta-Lactamase (by Double Disc Synergy
Test) in Nosocomial and Community-Acquired Infection
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According to the CLSI 2013, in ESBL-producing microor-
ganisms, bacteria isolates were resistant to cefotaxime
with MIC ≥ 64 µg/mL and ceftazidime with MIC ≥ 32
µg/mL. The MIC for cefotaxime, ceftazidime and ceftri-
axone was determined by E-test strip, according to the
CLSI for phenotypic ESBL-producing K. pneumoniae isolates
from UTI. In patients with nosocomial infection, resistance
of 64%, 45.3%, and 41.3%, and for community-acquired resis-
tance of 48%, 33.3% and 34.7% was obtained for ceftazidime,
cefotaxime and ceftriaxone, respectively. Multiplex PCR
analysis was performed for beta-lactamase genes TEM1,
SHV1, and VEB1 of nosocomial and community-acquired in-
fections. The multiplex PCR products of 189 bp TEM1, 256 bp
VEB1 and 389 bp SHV1 were analyzed using electrophoresis
on polyacrylamide gels (8%) (Figure 2).
In the nosocomial infection patients, 22 (29.3%) iso-
lates were positive for bla SHV1 gene, 18 (24%) were posi-
tive for the bla TEM1, and eight (10.7%) were positive for
the bla VEB1. Moreover, four (5.3%) isolates contained both
bla TEM1 and SHV1, one (1.3%) contained both blaTEM1 and
VEB1, and one (1.3%) contained both bla SHV1 and VEB1. For
the community-acquired infections, 17 (22.7%) isolates were
positive for bla SHV1, 13 (17.3%) were positive for bla TEM1
and six (8%) were positive for bla VEB1. In addition, one
(1.3%) isolate contained both bla TEM1 and SHV1, two (2.7%)
isolates contained both bla TEM1 and bla VEB1, and two
(2.7%) contained both blaSHV1 and bla VEB1.
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Table 1. Range of Minimal Inhibitory Concentrations of Ceftriaxone, Cefotaxime and Ceftazidime
Antimicrobial Agent Disk Content,µg Zone Diameter Interpretive Criteria,mma MIC Interpretive Criteria,µg/mL
Susceptible Intermediate Resistant Susceptible Intermediate Resistant
Ceftriaxone 30 ≥ 21 14 - 20 ≤ 13 ≤ 8 16 - 32 ≥ 64
Cefotaxime 30 ≥ 23 15 - 22 ≤ 14 ≤ 8 16 - 32 ≥ 64
Ceftazidime 30 ≥ 18 15 - 17 ≤ 14 ≤ 8 16 ≥ 32
Abbreviation: MIC, minimal inhibitory concentration.
aTo the nearest mm.
Table 2. Oligonucleotide Primers Used in the Study
Primers Sequences (5’ - 3’) Gen Type Product Size
TEM1 blaTEM1 189
F GCTATGTGGCGCGGTATTAT
R AAGTTGGCCGCAGTGTTATC
VEB1 blaVEB1 250
F GGGTATTCCAATCCTTGTGC
R CCCTCAAGACCTTTTGCCTA
SHV1 blaSHV1 389
F CCTCATTCAGTTCCGTTTCC
R CCGCGTAGGCATGATAGAAA
16SrRNA Internal 420
F AGGCCTTCGGGTTGTAAAGT
R ACCTCCAAGTCGACATCGTT
5. Discussion
Urinary tract infection is known as one of the most
common infections in patients with nosocomial and
community-acquired infections (1). Spread of drug resis-
tance factors among Gram-negative bacteria leads to the
appearance of strains resistant to antibiotics. These strains
cause development of UTIs resistant to antibiotic therapy
(17). Study in each area helps to identify the organisms
causing UTIs in that area, and determining the resistance
of bacteria to antimicrobial compounds that differ in dif-
ferent regions leads to the selection of appropriate treat-
ments for patients (18). The present study investigated
antibiotic susceptibility patterns of isolates of K. pneu-
moniae strains isolated from UTIs in patients with noso-
comial infections at university hospitals of Shahrkord,
Iran. The lowest resistance to antibiotics in the patients
with community-acquired infections was obtained for
imipenem (3%) followed by amikacin (31%), and nitrofuran-
toin (32%). The highest resistance to antibiotics in patients
with nosocomial infections was obtained for nalidixic acid
Figure 2. The Multiplex PCR Products
Line M, 100 bp marker; line P, positive control; line 1, 389bp SHV-1; line 2, 189bp TEM-1;
line 3, 250 bp VEB-1; line 4, TEM-1 and SHV-1; line 5, SHV-1 and VEB-1; line 6, TEM-1 and
VEB-1. All lines contain 420 bp fragment 16S rRNA.
(72%), followed by ceftazidime (63%), trimethoprim sul-
fametizol (61%), ciprofloxacin (60%), norfloxacin (59%), gen-
tamicin (59%) and nitrofurantoin (55%). According to these
findings, higher levels of antibiotic resistance were ob-
served in nosocomial infections compared to community-
acquired infections.
In a study conducted by Gholipour et al. in Isfahan,
Iran, antibiotic resistance to the above antibiotics was
lower than that obtained in the present study (6). In an-
other study by Eftekhar et al. in Tehran using antibiotic
discs, a higher antibiotic resistance than that obtained in
the present study was reported (2). Dallal et al. reported
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Table 3. Pattern of Antibiotic Susceptibility of the Klebsiella Strains From Urinary Tract Infections in Nosocomial and Community-Acquired Infections
Antibiotic Concentration,µg Nosocomiala Community-Acquireda
R I S R I S
AN 30 37 (49.3) 2 (2.7) 36 (48) 23 (30.7) 1 (1.3) 51 (68)
SXT 1.25/23.75 46 (61.3) 3 (4) 26 (34.7) 39 (52) 1 (1.3) 35 (46.7)
GM 10 44 (58.7) 1 (1.3) 30 (40) 29 (38.7) 1 (1.3) 45 (60)
FM 300 41 (54.7) 5 (6.6) 29 (38.7) 24 (32) 3 (4) 48 (64)
NOR 10 44 (58.7) 1 (1.3) 30 (40) 33 (44) 1 (1.3) 41 (54.7)
NA 30 54 (72) 5 (6.7) 16 (21.3) 40 (53.3) 5 (6.7) 30 (40)
CAZ 30 48 (64) 2 (2.7) 25 (33.3) 36 (48) 2 (2.7) 37 (49.3)
CTX 30 34 (45.3) 3 (4) 38 (50.7) 25 (33.3) 2 (2.7) 48 (64)
IPM 30 6 (8) 2 (2.7) 67 (89.3) 2 (2.7) 1 (1.3) 72 (96)
CRO 30 31 (41.3) 3 (4) 41 (54.7) 26 (34.7) 3 (4) 46 (61.3)
CIP 5 45 (60) 2 (2.7) 28 (37.3) 36 (48) 2 (2.7) 37 (49.3)
Abbreviations: AN, Amikacin; CAZ, Ceftazidime; CF, Cefpiem; CIP, Ciprofloxacin; CRO, Ceftriaxone; FM, Nitrofurantoin; GM, Gentamicin; I, intermediate; IPM, Impanel;
NA, Nalidixic acid; NOR, Norfloxacin; R, resistant; S, susceptible; SXT, Trimethoprim-sulfamethoxazole.
aValues are expressed as No. (%).
74%, 59% and 57% resistance to nalidixic acid, ciprofloxacin
and ceftazidime, respectively (19), which is in line with the
findings of the present study. The MIC of ceftazidime, ce-
fotaxime and ceftriaxone was evaluated, as well. In noso-
comial infection patients the resistance of ceftazidime, ce-
fotaxime and ceftriaxone was reported as 75%, 70.8% and
47.9%, respectively, and in those with community-acquired
infections, the resistance was reported as 58.9%, 53.8% and
30.7%, respectively. Irajian et al. assessed cefotaxime re-
sistance using the E-test and reported 22.4% resistance for
cefotaxime, which is lower than that of the present study
(20). In addition, Feizabadi et al. (21) and Mirsalehian et al.
(22) reported that the resistance levels to cefotaxime was
84% and 98%, respectively, which is higher than that in the
present study.
In a study conducted in Tabriz, cefotaxime resistance
was similar to our findings (23). Resistance to cefotaxime
using E-test strips has been evaluated in other countries.
In a study conducted by Akpaka et al. in Canada, resistance
was 44.3%, less than that in the present study (24). Tofte-
land et al. in Norway reported that 60% of the patients
characterized with phenotype ESBLs were somewhat resis-
tant to cephalosporin (25). Following the treatment of UTI
with beta-lactam antibiotics, particularly cephalosporins,
it is possible for antibiotics to acquire resistance factors
with respect to the acquisition by microorganisms (26).
Klebsiella pneumoniae is a common cause of urinary infec-
tions (27). The main cause of bacterial resistance to beta-
lactam antibiotics, particularly various cephalosporins, is
the presence of ESBL enzymes in bacteria (28). The preva-
lence of the bacteria producing ESBLs and resistance to
beta-lactam drugs are growing (29). Considering the lack
of efficacy of these antibiotics (beta-lactam) in the treat-
ment of infections caused by microorganisms producing
ESBLs, it is necessary to assess the antibiotic resistance pat-
terns (30). Here, the prevalence of ESBL in K. pneumoniae
isolate strains causing UTI in patients with nosocomial and
community-acquired infection was investigated.
Since beta-lactamase genes are derived from TEM1, thus
TEM1 and SHV1 as the beta-lactamase genes were studied
along VEB1. They are principal factors of hydrolysis com-
pounds such as monobactam and various cephalosporins.
The strains of K. pneumoniae-producing ESBLs in noso-
comial and community-acquired settings were 64% and
48%, respectively, suggesting a higher prevalence of these
enzymes in patients with nosocomial infections for cer-
tain reasons such as prolonged treatment procedures and
frequent use of urinary catheters during hospitalization.
The researches in other regions have reported higher
ESBL enzymes prevalence in inpatients than patients with
community-acquired infection (31). Zaniani et al. reported
ESBL outbreak of E. coli and K. pneumoniae of 43.9% and
56.1%, respectively, in Mashhad (32). Studying K. pneumo-
niae strains isolated from UTI, Jalalpour reported the preva-
lence of ESBL in patients with community-acquired and
nosocomial infections as 22% and 64%, respectively (33).
Therefore, our findings are consistent with his findings re-
garding the prevalence of ESBLs in ambulatory patients be-
ing higher than patients with community-acquired infec-
tion, and hence monitoring these patients and identifying
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ESBL-producing organisms and therapeutic interventions
for patients might be promising to prevent outbreaks.
The outbreaks of ESBL-producing K. pneumoniae isolate
strains have been reported in various studies. Gholipour
et al. reported the prevalence of ESBL-producing K. pneu-
moniae isolates as approximately 38.1% (6). Feizabadi et al.
found that the outbreak of the same isolates was about
44.5% (30). Aminzadeh et al. derived the amount of K. pneu-
moniae as 52.5% (34) and also Bazzaz et al. reported ESBL-
producing isolates of K. pneumoniae and E. coli as 59.2% (35).
Mobasherizadeh et al. reported the prevalence of ESBLs in
E. coli isolates from nosocomial and community-acquired
infections as 64% and 56%, respectively (36). Faizabadi et
al., in a study conducted in Tehran on 104 isolates of K. pneu-
moniae, reported the prevalence of ESBLs as 72.1% (21). In a
study by Mirsalehian et al., the prevalence of ESBLs was re-
ported as 59.3% (37).
The prevalence of ESBL enzymes has also been investi-
gated in other countries. In Korea, the prevalence of ESBL
was found to be 30% (38). In Pakistan, the prevalence of
ESBLs in K. pneumoniae isolates was reported as 36% (39).
In a study in India, 68% of K. pneumoniae strains isolated
from clinical specimens contained ESBLs-producing iso-
lates (40). Studies have also shown an increase in ESBL-
producing strains of K. pneumoniae, including 20% in Alge-
ria (41), 29% in Spain (42), 28.4% in Taiwan (43), and 44% in
the USA (44). In light of the above findings, it is clear that
the prevalence of a wide variety of ESBL enzymes is rising. It
seems that increased and prolonged duration of hospital-
ization and treatment procedures as well as frequent use of
urinary catheters in hospitals are responsible for the emer-
gence of resistant strains and transfer of resistant genes to
other bacteria. On the other hand, indiscriminate and ar-
bitrary use of beta-lactam drugs for community-acquired
infections causes emergence of resistant strains and their
outbreaks.
The majority of ESBL enzymes have appeared upon
changes in the structure of TEM and SHV enzymes. These
genes are abundant in the Enterobacteriaceae family, espe-
cially K. pneumoniae strains (45). The VEB gene is also fre-
quently found among strains of P. aeruginosa and other
members of the Enterobacteriaceae family (8). By mul-
tiplex PCR in this study, the prevalence of genes SHV1,
TEM1 and VEB1 in Klebsiella spp. isolate strains in pa-
tients with nosocomial and community-acquired infec-
tions was derived 29.3%, 24% and 10.6%, and 21.3%, 16% and
6.6%, respectively. This indicates the high level of expres-
sion of these genes in nosocomial rather than community-
acquired infections. While the TEM1 gene has already been
the most abundant beta-lactamase, several studies con-
ducted worldwide suggest a higher prevalence of SHV1
compared to TEM1 (46). In this study, although a number of
isolates were resistant to multiple drug classes, there was a
lack of beta-lactamase genes, which could be attributed to
the presence of other beta-lactamase genes. This requires
further investigation.
According to the present study, the prevalence of beta-
lactamase genes in Shahrekord hospitals is high. There-
fore, in order to control the spread of resistant strains,
appropriate supportive measures, reduction of healthcare
costs for patients with UTIs, and further research to deter-
mine antibiotic resistance patterns in the region are essen-
tial.
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